Severe cutaneous adverse reactions to drugs

Roujeau, 1994, Severe adverse cutaneous reactions to drugs, N Engl J Med, 331, 1272, 10.1056/NEJM199411103311906 Kardaun, 2013, Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study, Br J Dermatol, 169, 1071, 10.1111/bjd.12501 Auquier-Dunant, 2002, Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study, Arch Dermatol, 138, 1019, 10.1001/archderm.138.8.1019 Bastuji-Garin, 2000, SCORTEN: a severity-of-illness score for toxic epidermal necrolysis, J Invest Dermatol, 115, 149, 10.1046/j.1523-1747.2000.00061.x Valeyrie-Allanore, 2013, Prognostic value of histologic features of toxic epidermal necrolysis, J Am Acad Dermatol, 68, e29, 10.1016/j.jaad.2011.10.007 Bocquet, 1996, Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS), Semin Cutan Med Surg, 15, 250, 10.1016/S1085-5629(96)80038-1 Descamps, 2001, Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms, Arch Dermatol, 137, 301 Kano, 2006, Several herpesviruses can reactivate in a severe drug-induced multiorgan reaction in the same sequential order as in graft-versus-host disease, Br J Dermatol, 155, 301, 10.1111/j.1365-2133.2006.07238.x Kardaun, 2007, Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?, Br J Dermatol, 156, 609, 10.1111/j.1365-2133.2006.07704.x Shiohara, 2007, The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations, Br J Dermatol, 156, 1083, 10.1111/j.1365-2133.2007.07807.x Ortonne, 2015, Histopathology of drug rash with eosinophilia and systemic symptoms syndrome: a morphological and phenotypical study, Br J Dermatol, 173, 50, 10.1111/bjd.13683 Sidoroff, 2001, Acute generalized exanthematous pustulosis (AGEP)—a clinical reaction pattern, J Cutan Pathol, 28, 113, 10.1034/j.1600-0560.2001.028003113.x Kardaun, 2010, The histopathological spectrum of acute generalized exanthematous pustulosis (AGEP) and its differentiation from generalized pustular psoriasis, J Cutan Pathol, 37, 1220, 10.1111/j.1600-0560.2010.01612.x Pirmohamed, 2011, The phenotype standardization project: improving pharmacogenetic studies of serious adverse drug reactions, Clin Pharmacol Ther, 89, 784, 10.1038/clpt.2011.30 Roujeau, 1995, Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis, N Engl J Med, 333, 1600, 10.1056/NEJM199512143332404 Sassolas, 2010, ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis, Clin Pharmacol Ther, 88, 60, 10.1038/clpt.2009.252 Tomaino, 2012, Stevens-Johnson syndrome after Mycoplasma pneumonia infection in pediatric post-liver transplant recipient: case report and review of the literature, Pediatr Transplant, 16, E74, 10.1111/j.1399-3046.2010.01424.x Bequignon, 2015, Stevens-Johnson syndrome and toxic epidermal necrolysis: ear, nose, and throat description at acute stage and after remission, JAMA Dermatol, 151, 302, 10.1001/jamadermatol.2014.4844 Gueudry, 2009, Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis, Arch Dermatol, 145, 157 Lebargy, 1997, Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study, Intensive Care Med, 23, 1237, 10.1007/s001340050492 Chanal, 2013, Linear IgA bullous dermatosis: comparison between the drug-induced and spontaneous forms, Br J Dermatol, 169, 1041, 10.1111/bjd.12488 Cho, 2014, Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome/toxic epidermal necrolysis by immunohistopathological features, J Am Acad Dermatol, 70, 539, 10.1016/j.jaad.2013.11.015 Chung, 2013, Clinicopathologic analysis of coxsackievirus a6 new variant induced widespread mucocutaneous bullous reactions mimicking severe cutaneous adverse reactions, J Infect Dis, 208, 1968, 10.1093/infdis/jit383 Klimas, 2016, Bullae and atypical target lesions in a young woman, JAMA Dermatol Shiohara, 2006, Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses, Allergol Int, 55, 1, 10.2332/allergolint.55.1 Eshki, 2009, Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure, Arch Dermatol, 145, 67, 10.1001/archderm.145.1.67 Ishida, 2014, The dynamics of herpesvirus reactivations during and after severe drug eruptions: their relation to the clinical phenotype and therapeutic outcome, Allergy, 69, 798, 10.1111/all.12410 Sidoroff, 2007, Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR), Br J Dermatol, 157, 989, 10.1111/j.1365-2133.2007.08156.x Choi, 2010, Clinicopathologic manifestations of 36 Korean patients with acute generalized exanthematous pustulosis: a case series and review of the literature, Ann Dermatol, 22, 163, 10.5021/ad.2010.22.2.163 Hotz, 2013, Systemic involvement in acute generalized exanthematous pustulosis: a retrospective study of 58 cases, Br J Dermatol, 169, 1223, 10.1111/bjd.12502 Navarini, 2015, Homozygous missense mutation in IL36RN in generalized pustular dermatosis with intraoral involvement compatible with both AGEP and generalized pustular psoriasis, JAMA Dermatol, 151, 452, 10.1001/jamadermatol.2014.3848 Bouvresse, 2012, Toxic epidermal necrolysis, DRESS, AGEP: do overlap cases exist?, Orphanet J Rare Dis, 7, 72, 10.1186/1750-1172-7-72 Morel, 2011, Expression of α-defensin 1-3 in T cells from severe cutaneous drug-induced hypersensitivity reactions, Allergy, 66, 360, 10.1111/j.1398-9995.2010.02484.x Pichler, 2011, Immune pathomechanism of drug hypersensitivity reactions, J Allergy Clin Immunol, 127, S74, 10.1016/j.jaci.2010.11.048 Takahashi, 2009, Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome, J Immunol, 182, 8071, 10.4049/jimmunol.0804002 Padovan, 1996, T cell recognition of penicillin G: structural features determining antigenic specificity, Eur J Immunol, 26, 42, 10.1002/eji.1830260107 Wei, 2012, Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome, J Allergy Clin Immunol, 129, 1562, 10.1016/j.jaci.2011.12.990 Illing, 2012, Immune self-reactivity triggered by drug-modified HLA-peptide repertoire, Nature, 486, 554, 10.1038/nature11147 Ostrov, 2012, Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire, Proc Natl Acad Sci USA, 109, 9959, 10.1073/pnas.1207934109 Cheng, 2014, HLA associations and clinical implications in T-cell mediated drug hypersensitivity reactions: an updated review, J Immunol Res, 2014, 565320, 10.1155/2014/565320 Chung, 2004, Medical genetics: a marker for Stevens-Johnson syndrome, Nature, 428, 486, 10.1038/428486a Hung, 2005, HLA–B*58:01 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol, Proc Natl Acad Sci USA, 102, 4134, 10.1073/pnas.0409500102 Lonjou, 2008, A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs, Pharmacogenet Genomics, 18, 99, 10.1097/FPC.0b013e3282f3ef9c Mallal, 2008, HLA–B*57:01 screening for hypersensitivity to abacavir, N Engl J Med, 358, 568, 10.1056/NEJMoa0706135 Saag, 2008, High sensitivity of human leukocyte antigen–B*57:01 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients, Clin Infect Dis, 46, 1111, 10.1086/529382 Kaniwa, 2010, HLA–B*15:11 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients, Epilepsia, 51, 2461, 10.1111/j.1528-1167.2010.02766.x Génin, 2011, Genome-wide association study of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe, Orphanet J Rare Dis, 6, 52, 10.1186/1750-1172-6-52 McCormack, 2011, HLA–A*31:01 and carbamazepine-induced hypersensitivity reactions in Europeans, N Engl J Med, 364, 1134, 10.1056/NEJMoa1013297 Carr, 2013, Association of human leukocyte antigen alleles and Nevirapine hypersensitivity in a malawian HIV-infected population, Clin Infect Dis, 56, 1330, 10.1093/cid/cit021 Navarini, 2013, Rare variations in IL36RN in severe adverse drug reactions manifesting as acute generalized exanthematous pustulosis, J Invest Dermatol, 133, 1904, 10.1038/jid.2013.44 Ko, 2011, Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome, J Allergy Clin Immunol, 128, 1266, 10.1016/j.jaci.2011.08.013 Chung, 2015, Oxypurinol-specific T cells possess preferential TCR clonotypes and express granulysin in allopurinol-induced severe cutaneous adverse reactions, J Invest Dermatol, 135, 2237, 10.1038/jid.2015.165 Chung, 2014, Genetic variants associated with phenytoin-related severe cutaneous adverse reactions, JAMA, 312, 525, 10.1001/jama.2014.7859 Nicoletti, 2015, ABC transporters and the proteasome complex are implicated in susceptibility to Stevens-Johnson syndrome and toxic epidermal necrolysis across multiple drugs, PLoS One, 10, e0131038, 10.1371/journal.pone.0131038 de Araujo, 2011, Death ligand TRAIL, secreted by CD1a+ and CD14+ cells in blister fluids, is involved in killing keratinocytes in toxic epidermal necrolysis, Exp Dermatol, 20, 107, 10.1111/j.1600-0625.2010.01176.x Wang, 2013, A new nucleic acid-based agent inhibits cytotoxic T lymphocyte-mediated immune disorders, J Allergy Clin Immunol, 132, 713, 10.1016/j.jaci.2013.04.036 Tohyama, 2012, Possible involvement of CD14+ CD16+ monocyte lineage cells in the epidermal damage of Stevens-Johnson syndrome and toxic epidermal necrolysis, Br J Dermatol, 166, 322, 10.1111/j.1365-2133.2011.10649.x Chung, 2008, Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis, Nat Med, 14, 1343, 10.1038/nm.1884 Viard-Leveugle, 2013, TNF-α and IFN-γ are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis, J Invest Dermatol, 133, 489, 10.1038/jid.2012.330 Su, 2016, Interleukin-15 is associated with severity and mortality in Stevens-Johnson syndrome/toxic epidermal necrolysis, J Invest Dermatol Kim, 2015, Upregulated RIP3 expression potentiates MLKL phosphorylation-mediated programmed necrosis in toxic epidermal necrolysis, J Invest Dermatol, 135, 2021, 10.1038/jid.2015.90 Hashizume, 2013, Skin recruitment of monomyeloid precursors involves human herpesvirus-6 reactivation in drug allergy, Allergy, 68, 681, 10.1111/all.12138 Picard, 2010, Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response, Sci Transl Med, 2, 46ra62, 10.1126/scitranslmed.3001116 Filì, 2014, Hapten-specific TH17 cells in the peripheral blood of β-lactam-induced AGEP, Allergol Int, 63, 129, 10.2332/allergolint.13-LE-0582 Schlapbach, 2011, NKp46+ cells express granulysin in multiple cutaneous adverse drug reactions, Allergy, 66, 1469, 10.1111/j.1398-9995.2011.02677.x Fujita, 2011, Rapid immunochromatographic test for serum granulysin is useful for the prediction of Stevens-Johnson syndrome and toxic epidermal necrolysis, J Am Acad Dermatol, 65, 65, 10.1016/j.jaad.2010.04.042 Nomura, 2011, Evaluation of serum cytokine levels in toxic epidermal necrolysis and Stevens-Johnson syndrome compared with other delayed-type adverse drug reactions, J Dermatol, 38, 1076, 10.1111/j.1346-8138.2010.01170.x Yoshioka, 2013, Disturbed balance in three subpopulations of CD4(+)Foxp3(+) regulatory T cells in Stevens-Johnson syndrome and toxic epidermal necrolysis patients, Clin Immunol, 148, 89, 10.1016/j.clim.2013.04.002 Morito, 2014, Increased ratio of FoxP3+ regulatory T cells/CD3+ T cells in skin lesions in drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms, Clin Exp Dermatol, 39, 284, 10.1111/ced.12246 Hanafusa, 2012, The predominant drug-specific T-cell population may switch from cytotoxic T cells to regulatory T cells during the course of anticonvulsant-induced hypersensitivity, J Dermatol Sci, 65, 213, 10.1016/j.jdermsci.2011.12.002 Stern, 2012, Clinical practice. Exanthematous drug eruptions, N Engl J Med, 366, 2492, 10.1056/NEJMcp1104080 Kaffenberger, 2014, Toxic epidermal necrolysis and early transfer to a regional burn unit: is it time to reevaluate what we teach?, J Am Acad Dermatol, 71, 195, 10.1016/j.jaad.2013.12.048 Palmieri, 2002, A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century, J Burn Care Rehabil, 23, 87, 10.1097/00004630-200203000-00004 Valeyrie-Allanore, 2010, Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis, Br J Dermatol, 163, 847, 10.1111/j.1365-2133.2010.09863.x Struck, 2010, Severe cutaneous adverse reactions: emergency approach to non-burn epidermolytic syndromes, Intensive Care Med, 36, 22, 10.1007/s00134-009-1659-1 Creamer, 2016, UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016, Br J Dermatol, 174, 1194, 10.1111/bjd.14530 Garcia-Doval, 2000, Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?, Arch Dermatol, 136, 323, 10.1001/archderm.136.3.323 Rajaratnam, 2010, Toxic epidermal necrolysis: retrospective analysis of 21 consecutive cases managed at a tertiary center, Clin Exp Dermatol, 35, 853, 10.1111/j.1365-2230.2010.03826.x Weinand, 2013, 27 years of a single burn centre experience with Stevens-Johnson syndrome and toxic epidermal necrolysis: analysis of mortality risk for causative agents, Burns, 39, 1449, 10.1016/j.burns.2013.03.011 de Prost, 2014, Acute respiratory failure in patients with toxic epidermal necrolysis: clinical features and factors associated with mechanical ventilation, Crit Care Med, 42, 118, 10.1097/CCM.0b013e31829eb94f Firoz, 2012, Toxic epidermal necrolysis: five years of treatment experience from a burn unit, J Am Acad Dermatol, 67, 630, 10.1016/j.jaad.2011.12.014 Lin, 2011, Management of ocular conditions in the burn unit: thermal and chemical burns and Stevens-Johnson syndrome/toxic epidermal necrolysis, J Burn Care Res, 32, 547, 10.1097/BCR.0b013e31822b0f29 Liu, 2011, Oral mucosal graft with amniotic membrane transplantation for total limbal stem cell deficiency, Am J Ophthalmol, 152, 739, 10.1016/j.ajo.2011.03.037 Schneck, 2008, Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study, J Am Acad Dermatol, 58, 33, 10.1016/j.jaad.2007.08.039 Sekula, 2013, Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis, J Invest Dermatol, 133, 1197, 10.1038/jid.2012.510 Lee, 2012, The role of prior corticosteroid use on the clinical course of Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control analysis of patients selected from the multinational EuroSCAR and RegiSCAR studies, Br J Dermatol, 167, 555, 10.1111/j.1365-2133.2012.11074.x Paradisi, 2014, Etanercept therapy for toxic epidermal necrolysis, J Am Acad Dermatol, 71, 278, 10.1016/j.jaad.2014.04.044 Bachot, 2003, Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression, Arch Dermatol, 139, 33, 10.1001/archderm.139.1.33 Chen, 2010, High-dose intravenous immunoglobulins in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese patients: a retrospective study of 82 cases, Eur J Dermatol, 20, 743 Huang, 2012, The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis, Br J Dermatol, 167, 424, 10.1111/j.1365-2133.2012.10965.x Lee, 2013, The role of intravenous immunoglobulin in toxic epidermal necrolysis: a retrospective analysis of 64 patients managed in a specialized centre, Br J Dermatol, 169, 1304, 10.1111/bjd.12607 Kirchhof, 2014, Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine, J Am Acad Dermatol, 71, 941, 10.1016/j.jaad.2014.07.016 de Sica-Chapman, 2010, Granulocyte colony-stimulating factor in toxic epidermal necrolysis (TEN) and Chelsea & Westminster TEN management protocol, Br J Dermatol, 162, 860, 10.1111/j.1365-2133.2009.09585.x Wolkenstein, 1998, Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis, Lancet, 352, 1586, 10.1016/S0140-6736(98)02197-7 Chen, 2010, Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases, Arch Dermatol, 146, 1373, 10.1001/archdermatol.2010.198 Natkunarajah, 2011, Ten cases of drug reaction with eosinophilia and systemic symptoms (DRESS) treated with pulsed intravenous methylprednisolone, Eur J Dermatol, 21, 385, 10.1684/ejd.2011.1300 Joly, 2012, Poor benefit/risk balance of intravenous immunoglobulins in DRESS, Arch Dermatol, 148, 543, 10.1001/archderm.148.4.dlt120002-c Funck-Brentano, 2015, Therapeutic management of DRESS: a retrospective study of 38 cases, J Am Acad Dermatol, 72, 246, 10.1016/j.jaad.2014.10.032 Ingen-Housz-Oro, 2015, Acute generalized exanthematous pustulosis: a retrospective audit of practice between 1994 and 2011 at a single centre, Br J Dermatol, 172, 1455, 10.1111/bjd.13540 de Prost, 2010, Bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: epidemiology, risk factors, and predictive value of skin cultures, Medicine (Baltimore), 89, 28, 10.1097/MD.0b013e3181ca4290 Knight, 2015, Stevens Johnson syndrome and toxic epidermal necrolysis: maternal and foetal outcomes in twenty-two consecutive pregnant HIV infected women, PLoS One, 10, e0135501, 10.1371/journal.pone.0135501 Wu, 2015, Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with malignancies, Br J Dermatol, 173, 1224, 10.1111/bjd.14052 Guégan, 2006, Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis, J Invest Dermatol, 126, 272, 10.1038/sj.jid.5700068 Sekula, 2011, Evaluation of SCORTEN on a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis included in the RegiSCAR study, J Burn Care Res, 32, 237, 10.1097/BCR.0b013e31820aafbc Duong, 2015, Stevens-Johnson syndrome and toxic epidermal necrolysis: follow-up of pulmonary function after remission, Br J Dermatol, 172, 400, 10.1111/bjd.13505 Gaultier, 2009, Severe and unrecognized dental abnormalities after drug-induced epidermal necrolysis, Arch Dermatol, 145, 1332, 10.1001/archdermatol.2009.233 Yang, 2016, Long-term sequelae of Stevens-Johnson syndrome/toxic epidermal necrolysis, Acta Derm Venereol, 96, 525, 10.2340/00015555-2295 Sant' Anna, 2012, Minor salivary glands and labial mucous membrane graft in the treatment of severe symblepharon and dry eye in patients with Stevens-Johnson syndrome, Br J Ophthalmol, 96, 234, 10.1136/bjo.2010.199901 Tougeron-Brousseau, 2009, Vision-related function after scleral lens fitting in ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis, Am J Ophthalmol, 148, 852, 10.1016/j.ajo.2009.07.006 Struck, 2010, Toxic epidermal necrolysis in pregnancy: case report and review of the literature, J Burn Care Res, 31, 816, 10.1097/BCR.0b013e3181eed441 Chen, 2013, Long-term sequelae of drug reaction with eosinophilia and systemic symptoms: a retrospective cohort study from Taiwan, J Am Acad Dermatol, 68, 459, 10.1016/j.jaad.2012.08.009 Lew, 2015, Post-traumatic stress disorder following drug reaction with eosinophilia and systemic symptoms, Br J Dermatol, 172, 836, 10.1111/bjd.13375 Tohyama, 2007, Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome, Br J Dermatol, 157, 934, 10.1111/j.1365-2133.2007.08167.x Kano, 2010, Visceral involvements and long-term sequelae in drug-induced hypersensitivity syndrome, Med Clin North Am, 94, 743, 10.1016/j.mcna.2010.03.004 Ushigome, 2013, Short- and long-term outcomes of 34 patients with drug-induced hypersensitivity syndrome in a single institution, J Am Acad Dermatol, 68, 721, 10.1016/j.jaad.2012.10.017 Bégaud, 1985, Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France, Therapie, 40, 111 Naranjo, 1981, A method for estimating the probability of adverse drug reactions, Clin Pharmacol Ther, 30, 239, 10.1038/clpt.1981.154 Mockenhaupt, 2008, Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study, J Invest Dermatol, 128, 35, 10.1038/sj.jid.5701033 Chaponda, 2011, Hypersensitivity reactions to HIV therapy, Br J Clin Pharmacol, 71, 659, 10.1111/j.1365-2125.2010.03784.x Kuehn, 2013, FDA: Acetaminophen may trigger serious skin problems, JAMA, 310, 785, 10.1001/jama.2013.276938 Levi, 2009, Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis, Pediatrics, 123, e297, 10.1542/peds.2008-1923 Raucci, 2013, Stevens-Johnson syndrome associated with drugs and vaccines in children: a case-control study, PLoS One, 8, e68231, 10.1371/journal.pone.0068231 Roujeau, 2013, Telaprevir-related dermatitis, JAMA Dermatol, 149, 152, 10.1001/jamadermatol.2013.938 Valeyrie-Allanore, 2008, Stevens-Johnson syndrome and toxic epidermal necrolysis induced by amifostine during head and neck radiotherapy, Radiother Oncol, 87, 300, 10.1016/j.radonc.2008.01.021 Haddad, 2017, Are idiopathic Stevens-Johnson syndrome/toxic epidermal necrolysis related to drugs in food? The example of phenylbutazone, J Invest Dermatol, 10.1016/j.jid.2016.11.041 Ziemer, 2012, Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus: a descriptive study of 17 cases from a national registry and review of the literature, Br J Dermatol, 166, 575, 10.1111/j.1365-2133.2011.10705.x Wolkenstein, 2005, Association analysis of drug metabolizing enzyme gene polymorphisms in AIDS patients with cutaneous reactions to sulfonamides, J Invest Dermatol, 125, 1080, 10.1111/j.0022-202X.2005.23939.x Adam, 2014, Abacavir induced T cell reactivity from drug naïve individuals shares features of allo-immune responses, PLoS One, 9, e95339, 10.1371/journal.pone.0095339 Chen, 2011, Carbamazepine-induced toxic effects and HLA–B*15:02 screening in Taiwan, N Engl J Med, 364, 1126, 10.1056/NEJMoa1009717 Yang, 2015, Allopurinol use and risk of fatal hypersensitivity reactions: a nationwide population-based study in Taiwan, JAMA Intern Med, 175, 1550, 10.1001/jamainternmed.2015.3536 Picard, 2015, Recurrence of drug-induced reactions in DRESS patients, J Eur Acad Dermatol Venereol, 29, 801, 10.1111/jdv.12419 Finkelstein, 2014, Recurrence and mortality following severe cutaneous adverse reactions, JAMA, 311, 2231, 10.1001/jama.2014.839 Stern, 2014, Recurrence of Stevens-Johnson syndrome and toxic epidermal necrolysis, JAMA, 312, 1590, 10.1001/jama.2014.10777 Barbaud, 2013, A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions, Br J Dermatol, 168, 555, 10.1111/bjd.12125 Kano, 2007, Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption, Allergy, 62, 1439, 10.1111/j.1398-9995.2007.01553.x Srinoulprasert, 2014, Enhancement of drug-specific lymphocyte proliferation using CD25-depleted CD3(+) effector cells, Int Arch Allergy Immunol, 163, 198, 10.1159/000358491 Polak, 2013, In vitro diagnostic assays are effective during the acute phase of delayed-type drug hypersensitivity reactions, Br J Dermatol, 168, 539, 10.1111/bjd.12109 Porebski, 2013, In vitro drug causality assessment in Stevens-Johnson syndrome—alternatives for lymphocyte transformation test, Clin Exp Allergy, 43, 1027, 10.1111/cea.12145 Haddad, 2013, Stevens-Johnson syndrome/toxic epidermal necrolysis: are drug dictionaries correctly informing physicians regarding the risk?, Drug Saf, 36, 681, 10.1007/s40264-013-0070-6 Isvy-Joubert, 2014, Severe cutaneous adverse reactions to drugs: from patients to the national office for compensation of medical accidents, Dermatology (Basel), 228, 338, 10.1159/000358295 Lebrun-Vignes, 2012, Comparative analysis of adverse drug reactions to tetracyclines: results of a French national survey and review of the literature, Br J Dermatol, 166, 1333, 10.1111/j.1365-2133.2012.10845.x Ketter, 2006, The effect of dermatologic precautions on the incidence of rash with addition of lamotrigine in the treatment of bipolar I disorder: a randomized trial, J Clin Psychiatry, 67, 400, 10.4088/JCP.v67n0310 Phoenix, 2012, Diagnosis and management of cellulitis, BMJ, 345, e4955, 10.1136/bmj.e4955